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Over the past few years, the survival rate for all cancers has improved considerably.1 The improvement has 
been ascribed to a combination of early detection 
and better treatment strategies and modalities. 
With the advent of systemic treatment, more 
and more cancers are being cured, whether they 
were seemingly localised, or even metastatic at 
presentation. The improvement in survival has 
been for most of the part in small incremental gains; 
however, there have also been some quantum leaps. 
A glance at the last half century reveals that by 
1961, with the advent of combination chemotherapy 
including nitrogen mustard compounds, more than 
60% patients with Hodgkin’s lymphoma (HL) could 
be cured.2 This outcome was improved further 
by using non-nitrogen mustard combination 
chemotherapy, which not only improved the 
chances of survival by almost 10%, but also 
significantly reduced the long-term toxic effects, 
such as infertility and secondary cancers.3 Today, 
80–90% of the patients diagnosed to have HL are 
cured of their illness. 
The next major advance was the advent of 
cisplatin which transformed the management of 
certain cancers, such as the germ cell cancers; 
they became curable in more than 80% of patients, 
even when the cancer was metastatic at the 
time of presentation.4 To date, cisplatin-based 
chemotherapy remains the standard of care for 
these cancers. 
The third major advance was the realisation that 
the addition of chemotherapy to surgery improved 
the outcomes of patients with breast cancer. Two 
groups working independently in the United States 
and Italy published landmark studies showing that 
the addition of chemotherapy after mastectomy 
improved the survival of patients with localised and 
locally advanced breast cancer.5,6
The fourth major advance was the use of 
allogeneic transplants which were to change the 
outlook for patients with relapsed acute leukaemia.7,8 
However, allogeneic transplant is associated with 
significant toxicity, including mortality, preventing 
its use for the majority of patients with diseases in 
which it has been shown to be effective. 
The fifth major advance was the use of autologous 
stem cell transplant in patients with relapsed high 
grade non-Hodgkin’s lymphoma (NHL). It became 
the standard of care for relapsed NHL.9 
Although all these advances are considered 
quantum leaps, few treatment modalities have 
fundamentally changed the paradigm of cancer 
treatment. Except for the advent of cisplatin, and 
the use of adjuvant chemotherapy, none of these 
treatments or modalities changed the outlook for 
the majority of cancer patients, as the effects were 
limited either to the tumour type, or were limited 
by excess toxicity. Adjuvant and neo-adjuvant 
chemotherapies are now an integral part of the 
management plan for a vast majority of cancers. 
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In the late 1990s, two significant advances 
revolutionised the way cancer is treated today. The 
advent of anti-CD20 antibody and the antibody 
to the HER-2/neu protein expressed by breast 
cancers have significantly changed the way that 
B-cell lymphoma, and about 25% of breast cancers, 
are treated.10,11 The second major advance was the 
advent of a tyrosine kinase inhibitor (TKI), imatinib 
mesylate, which transformed the management and 
outcomes of chronic myeloid leukaemia (CML).12,13 
Both these two types of targeted treatment, the 
monoclonal antibodies and the TKIs, have resulted 
in a paradigm shift in the management of not only 
the cancers for which they were initially tested, but 
for an ever-expanding variety of cancer types. 
Tyrosine kinase (TK) is an enzyme which 
either activates or deactivates other proteins by 
transferring a phosphate molecule to tyrosine. The 
process is called phosphorylation, and may become 
uncontrolled in cancers.12 About 90 different 
TKs have been identified, two thirds of which are 
attached to trans-membrane receptors, and the 
rest are cytoplasmic.13 The TKs transduce signals 
through the cytoplasm, and are specific to cancers. 
For example, epidermal growth factor receptor 
(EGFR), a trans-membrane receptor, is closely 
related to c-erb B-2 oncogene, and is over-expressed 
in several cancers, including, breast cancer.14 TKs 
attached to EGFR are autophosphorylated in these 
cancers. Similarly, bcr-abl fusion protein, formed 
as a result of reciprocal translocation between 
long arms of chromosomes 9 and 22 in CML, is 
a cytoplasmic TK.15 Both types of TKs are either 
mutated or activated in several cancers, and have 
emerged as targets for TKIs, drugs specifically 
designed to block these TKs. A compound, 
previously called STI571, and now called imatinib 
mesylate, was first shown to inhibit the bcr-abl TK 
through competitive inhibition at the ATP-binding 
site of the enzyme, leading to inhibition of tyrosine 
phosphorylation, arresting the growth of the 
leukaemic cells, and inducing apoptosis.15 
In this issue of SQUMJ, Shaun McCann 
has reviewed the history of the diagnosis and 
management of CML, and has asked the question, 
whether CML is a strange disease or a paradigm for 
malignancy.16 It is intriguing to note that a disease 
characterised by abnormal white blood cells in the 
peripheral blood was first described even when 
the microscope had not been invented; the specific 
chromosomal translocation was defined as early 
as 1960, and the resultant fusion protein bcr-abl 
was described in 1990. The bcr-abl fusion protein 
is sufficient to cause CML, and the mutational 
studies established that phosphorylation of TK was 
required for oncogenic activity. Lack of technology 
was the limiting factor in exploitation of those 
discoveries and, for a long time, the treatment aimed 
at reducing the white blood cells in the peripheral 
blood, without affecting the natural history of the 
disease. Only interferon alpha (IFN-α) was shown 
to prolong survival marginally, but was associated 
with considerable toxicity.17 Once allogeneic 
transplantation became available, selected patients 
could be cured, but at the expense of significant 
mortality. Furthermore, transplantation was 
available to people who were otherwise fit, and had 
a suitable donor. It was only after developing the 
capacity to block the phosphorylation of the TK 
domain that a new form of treatment emerged. The 
drug received an unprecedented rapid approval by 
the Food and Drug Administration (FDA) authority 
of the USA following the publication of a phase I 
trial.18 This was several years before the publication 
of the first phase III trial,19 something considered by 
many as a pre-requisite for the approval of a new 
medicine by the FDA. 
So what brought about one of the greatest 
practice-changing concepts in the history of 
malignant haematology and medical oncology? In a 
proof-of-principle study, escalating doses of STI571 
were administered to 83 patients in the chronic 
phase of CML.18 All patients had failed to respond 
to treatment with the standard-of-care at that 
stage, IFN-α. Complete haematological responses 
were observed in 53 of 54 patients treated with a 
daily oral dose of more than 300 mg; cytogenetic 
responses occurred in 17 patients, and 7 patients 
had complete cytogenetic remission. Adverse events 
were minimal, merely nausea, myalgia, oedema, and 
diarrhoea. Since then, the outcome of patients with 
CML has changed forever. At 7 years, 86% of the 
patients are alive compared with a median survival 
of 2–3 years, just a decade ago.20 
So massive were the implications of TKIs 
that soon after the description of the activity of 
imatinib in CML, TK targets specific to other 
cancers were explored. Imatinib was also found 
to inhibit the TK associated with the c-KIT and 
platelet-derived growth factor (PDGFR), expressed 
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on gastrointestinal stromal tumours (GIST).21 
Metastatic GIST, so far known to be refractory to 
treatment, was treated with imatinib, and more 
than 80% of the patients receive clinical benefit. 
Not only did imatinib become the gold-standard of 
care for the treatment of metastatic GIST22 but it 
also became a model for the quest of targets in solid 
tumours. 
TKIs have now become the standard of care 
for the management of several cancers and 
are used either in combination with cytotoxic 
chemotherapy in breast cancer, or as a single agent 
in several difficult-to-treat cancers, such as the 
clear cell carcinoma of the kidney,23 hepatocellular 
carcinoma,24 adenocarcinoma of the lung,25,26 and 
melanoma.27 Despite the advances, there are several 
hurdles still to be overcome. The issue of primary 
and acquired resistance, side effects and ever-
increasing cost of medicines are real challenges, and 
need to be dealt with if TKIs are to have an impact 
on the vast majority of common cancers. 
For almost half a century, the treatment of cancer 
sat on a three-legged stool of surgery, radiotherapy 
and chemotherapy. With the addition of the 
targeted therapy in the last decade, it now seems 
to be sittting on a stable chair with four legs. Over 
the last 10 years, a total of 33 targeted agents have 
been approved by the FDA for treatment of various 
cancers. This is in comparison with 14 cytotoxic 
agents, approved during the same period.28 The 
advent of imatinib and its application in CML paved 
the way for the change. Registries have reported a 
reduction in the number of transplants for CML,29 
and in this ‘imatinib era’ patients are treated with 
tablets.30 TKIs and other targeted therapies are now 
being used either to cure cancers, or to convert 
cancer to chronic disease. CML has led the way 
this time. Truly, the disease has brought about a 
paradigm shift. 
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